Multiple System Atrophy clinical trials at University of California Health

10 in progress, 3 open to eligible people

Showing trials for

  • GDNF Gene Therapy for Multiple System Atrophy

    open to eligible people ages 35-75

    The objective of this randomized, double-blinded, placebo-controlled Phase 1 investigation is to evaluate the safety and potential clinical effect of AAV2-GDNF delivered to the putamen in subjects with either a possible or probable diagnosis of Multiple System Atrophy.

    at UC Irvine

  • Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy

    open to eligible people ages 30 years and up

    This is a Phase 3, multi-center, randomized withdrawal study to evaluate the efficacy and durability of ampreloxetine in participants with MSA and symptomatic nOH after 20 weeks of treatment. This study includes 4 periods: Screening, open label, randomized withdrawal, and long-term treatment extension (LTE).

    at UCLA UCSD

  • North American Prodromal Synucleinopathy Consortium Stage 2

    open to eligible people ages 18 years and up

    This study will enroll participants with idiopathic REM sleep behavior disorder (RBD) and healthy controls for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.

    at UCLA

  • ONO-2808 in Patients With Multiple System Atrophy

    Sorry, in progress, not accepting new patients

    This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of multiple doses of ONO-2808 in patients with MSA. This is the first study of ONO-2808 in patients with MSA.

    at UCLA

  • YA-101 in Patients with Multiple System Atrophy

    Sorry, not yet accepting patients

    This is a Phase 2, double-blind, placebo-controlled, multi-center, Phase II, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and efficacy of Ya-101 in subjects with multiple system atrophy.

    at UCLA

  • Lu AF82422 in Participants With Multiple System Atrophy

    Sorry, in progress, not accepting new patients

    To find out the effect of Lu AF82422 on disease progression in participants with multiple system atrophy.

    at UCSD UCSF

  • Parkinson's and Zoledronic Acid

    Sorry, in progress, not accepting new patients

    This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and older with Parkinson's disease and parkinsonism with at least 2 years of follow-up. A total of 2650 participants will be enrolled and randomized in the United States. Participants, follow-up outcome assessors, and study investigators will be blinded to assigned study treatment. This trial is funded by the National Institute of Aging.

    at UC Davis UC Irvine UCLA UCSF

  • Automated Imaging Differentiation of Parkinsonism

    Sorry, in progress, not accepting new patients

    The purpose of this study is to test the performance of the AID-P across 21 sites in the Parkinson Study Group. Each site will perform imaging, clinical scales, diagnosis, and will upload the data to the web-based software tool. The clinical diagnosis will be blinded to the diagnostic algorithm and the imaging diagnosis will be compared to the movement disorders trained neurologist diagnosis.

    at UCSD UCSF

  • North American Prodromal Synucleinopathy Consortium

    Sorry, accepting new patients by invitation only

    This study will enroll participants with idiopathic rapid eye movement (REM) sleep behavior disorder (RBD), for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.

    at UCLA

  • Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy

    Sorry, in progress, not accepting new patients

    The objective of this study is to describe disease progression in study participants diagnosed with early Parkinson's Disease or Multiple System Atrophy - Parkinsonian Type up to 18 months as delineated by clinical and biochemical parameters.

    at UC Irvine

Our lead scientists for Multiple System Atrophy research studies include .

Last updated: